Clicky

Anhui Anke BioTech Group(300009)

Description: Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.


Keywords: Pharmaceutical Pharmaceutical Products Tumor Immunotherapy Human Reproduction Fertility Reproduction Interferon Markets Pharmaceutical Products Semen Anti Aging Products Sperm

Home Page: www.ankebio.com

AnkeBio Building
Hefei, 230088
China
Phone: 86 551 6531 9890


Officers

Name Title
Mr. Lihua Song Chairman of Board of Directors and Pres
Mr. Yong Bin Wang Financial Director
Mr. Jian Ping Yao Sr. VP
Ms. She Wu Song VP & Director
Mr. Hai Sheng Sr. VP
Mr. Yong Biao Fu VP & Director
Mr. Xin Wen Yan Deputy Gen. Mang.
Ms. Hui Zhao VP & Director
Mr. Xing Li Sec. of the Board
Ms. Chunyan Lu VP

Exchange: SHE

Country: CN : China

Currency: Renminbi (¥)

Forward PE: 0
Trailing PE: 48.3043
Price-to-Book MRQ: 5.6711
Price-to-Sales TTM: 7.5827
IPO Date: 2009-10-30
Fiscal Year End: December
Full Time Employees: 0
Back to stocks